Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MPC2 | O95563 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98551 | 0.90 | FFAR1 (0.42) | FFAR1PPARACA2PPARGPTPN1 | |
| SCHEMBL13602443 | 0.89 | CA2 (0.48) | FFAR1PPARACA2PPARGPTPN1 | |
| SCHEMBL95205 | 0.89 | CA2 (0.45) | FFAR1PPARACA2PPARGPTPN1 | |
| SCHEMBL94894 | 0.86 | CA2 (0.47) | FFAR1CA2PPARGPTPN1 | |
| SCHEMBL13598457 | 0.86 | TGM2 (0.39) | FFAR1CA2PTPN1 | |
| SCHEMBL95070 | 0.86 | CA2 (0.48) | FFAR1CA2PPARGPTPN1MPC2 | |
| SCHEMBL98093 | 0.86 | CA2 (0.45) | FFAR1CA2PPARGPTPN1MPC2 | |
| SCHEMBL95913 | 0.86 | CA2 (0.46) | FFAR1PPARACA2PPARGPTPN1 | |
| SCHEMBL95628 | 0.86 | MAPT (0.47) | FFAR1CA2PPARGPTPN1MPC2 | |
| SCHEMBL97563 | 0.85 | CA2 (0.40) | FFAR1PPARACA2PPARGPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | FFAR1 2284/4885PPARA 3385/4885CA2 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.